Instituto Do Cancer Do Estado De São Paulo

This study looks at whether giving the immunotherapy drug pembrolizumab for one year works just as well as the usual two-year course for people with advanced melanoma that has spread. The trial involves 29 adults in Brazil whose melanoma cannot be removed by surgery or cured. The…

This study tests a new way of giving the drug regorafenib to people with advanced liver cancer. Instead of starting at a high dose, the dose is slowly increased over the first two treatment cycles to find the highest dose each person can handle without severe side effects. The go…